Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatology
•
Systemic autoimmune diseases
Do you see a role for early, aggressive treatment for MCTD to prevent progression of disease, even though there has not been end-organ manifestations?
Related Questions
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you approach managing nausea and GI side effects when initiating methotrexate?
What treatments have you found most effective for cholestatic pruritus?
How would you approach management of a patient with rapidly progressive systemic sclerosis with worsening skin disease, myositis, arthritis, dysphagia and failure to thrive developing within 6 months?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
How would you counsel a patient with systemic sclerosis who wants to consider microneedling on the face or other skin which is not clearly involved with scleroderma?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
